Ultra-thinly traded nano cap Anchiano Therapeutics (NASDAQ:ANCN) slumps 33% premarket on light volume in reaction its decision to terminate a Phase 2 clinical trial, Codex, evaluating gene therapy inodiftagene vixteplasmid in patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC).
The company decided to pull the plug due to the low probability of a successful outcome. It will focus its resources on its small-molecule pan-RAS inhibitor and PDE10/β-catenin inhibitor programs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.